Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended March 31, 2022. Net sales were $106.4 million, earnings per share (“EPS”) was $(0.22), and adjusted EPS was $(0.10). “We're very pleased with our financial and operational performance in the first quarter given the COVID-19 and labor headwinds, ongoing global supply chain disruptions, and macro financial impacts stemming from political instability in Europe. The str

Orthofix Reports First Quarter 2022 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix announces FDA pre-market approval for the AccelStim™ Bone Growth Stimulation device for indicated fresh fractures and nonunions.

FDA Grants PMA for the AccelStim Bone Growth Stimulation Device — Expanding Orthofix's Portfolio of Market-Leading Bone Healing Therapy Solutions

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix renews and expands agreement with MTF Biologics - extending exclusive marketing rights to the Trinity™ allograft line through 2032.

Orthofix and MTF Biologics Expand Partnership Agreement

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the first quarter 2022 before market open on Friday, May 6, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access the

Orthofix Medical Schedules First Quarter Earnings Release and Conference Call for May 6, 2022

LEWISVILLE, Texas--(BUSINESS WIRE)--Kimberley Elting, Chief Legal and Development Officer for Orthofix, Appointed to Lead Global Orthopedics Business

Orthofix Announces New Business Unit President

NuVasive

Stryker

Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.

Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus

LEWISVILLE, Texas--(BUSINESS WIRE)--The TrueLok EVO Ring Fixation system features radiolucent rings and struts to enable clear radiographic visualization of the anatomy during surgery.

Orthofix Announces FDA Clearance and First Patient Cases With the TrueLok EVO Ring Fixation System

The consensus price target hints at a 46.7% upside potential for Orthofix (OFIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Orthofix (OFIX) Could Rally 47%: Here's is How to Trade

Orthofix Medical Inc. (OFIX) CEO Jon Serbousek on Q4 2021 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of 107.69% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Tops Q4 Earnings and Revenue Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2021. Net sales for the fourth quarter were $125.1 million, earnings (loss) per share (“EPS”) was $(1.65) and adjusted EPS was $0.27. For fiscal year 2021, net sales were $464.5 million, EPS was $(1.95) and adjusted EPS was $0.86. “Despite the headwinds our industry faced throughout the year, we delivered double digit revenue grow

Orthofix Reports Fourth Quarter and Fiscal Year 2021 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix expands biologics portfolio with Opus BA, a synthetic bone graft solution for cervical and lumbar spine fusion procedures.

Orthofix Expands Synthetic Bone Growth Offerings with Full Market Launch of Opus BA – a Bioactive Solution for Spine Procedures

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the fourth quarter and full year 2021 before market open on Friday, February 25, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested p

Orthofix Medical Schedules Fourth Quarter and Full Year Earnings Release and Conference Call for February 25, 2022

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix and nView medical announce partnership to develop and co-market systems for cervical spine and pediatric limb deformity procedures.

Orthofix Announces Investment and Partnership with nView medical, Developer of Novel Imaging and Guidance Systems

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2021 net sales of approximately $125 million, an increase of 6% on a reported basis and 7% on a constant currency basis versus fourth quarter 2020. On a sequential basis, compared to the third quarter of 2021, net sales increased 11%. For the full year 2021, preliminary unaudited net sales were approximately $464 million, an increase of 14% on a reported basis and 13% on

Orthofix Announces Preliminary 2021 Fourth Quarter and Full Year Net Sales Results

Intersect ENT

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix names Thomas A. West to the Company's Board of Directors and appoints him to the Compensation and Talent Development Committee.

Orthofix Announces Appointment of Thomas A. West to Board of Directors

Orthofix Medical Inc. (OFIX) CEO Jon Serbousek on Q3 2021 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of -23.08% and -0.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Lags Q3 Earnings and Revenue Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended September 30, 2021. Net sales were $112 million, earnings per share (“EPS”) was $(0.11), and adjusted EPS was $0.10. “I am proud of the tenacity of our team as they continue to implement our strategic initiatives despite the ongoing challenges of COVID, delivering double-digit growth in both our global Spinal Implants and Orthopedics businesses,” said Orthofix Presi

Orthofix Reports Third Quarter 2021 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in two upcoming virtual investor conferences. Credit Suisse 30th Annual Healthcare Conference The Company will be presenting on Wednesday, November 10, 2021 at 3:30pm EST. Stifel 2021 Virtual Healthcare Conference The Company will

Orthofix Announces Participation in Upcoming Credit Suisse and Stifel Healthcare Conferences

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the third quarter 2021 before market open on Friday, November 5, 2021. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may acces

Orthofix Schedules Third Quarter Earnings Release and Conference Call for November 5, 2021

Orthofix Medical Inc. OFIX, -0.28% said Wednesday it expects third-quarter revenue growth to come in at a low single-digit increase over the year-earlier period

Medical device maker Orthofix warns that Q3 revenue will rise only in low-single digits as COVID delays procedures

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today provided a business update. The Company has experienced the impact of higher than expected volumes of deferred or rescheduled elective procedures resulting from hospital procedural restrictions, both in the U.S. and internationally, associated with the recent surge in COVID-19 Delta variant cases. As a result, the Company expects revenue growth for t

Orthofix Provides Business Update

Orthofix (OFIX) reveals that more than 60,000 M6-C artificial cervical discs have been implanted worldwide.

Orthofix (OFIX) Reaches Milestone for M6-C Disc Implants

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix announces that more than 60,000 M6-C artificial cervical discs have been implanted worldwide as an alternative to cervical fusion.

News for Orthofix International Stock (OFIX)